Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
نویسندگان
چکیده
منابع مشابه
Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
INTRODUCTION Prostate cancer is a large clinical burden across Europe. It is, in fact, the most common cancer in males, accounting for more than 92,300 deaths annually throughout the continent. Prostate cancer is androgen-sensitive; thus an androgen deprivation therapy (ADT) is often used for treatment by reducing androgen to castrate levels. Several ADT agents have achieved benefits with effec...
متن کاملLHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?
Crawford and Hou[1] review the data on luteinizing hormone-releasing hormone (LHRH) antagonists in prostate cancer. They describe the results of a phase III trial comparing monthly degarelix to monthly leuprolide in men with advanced prostate cancer. Degarelix treatment was associated with a more rapid decline of serum testosterone, and was not associated with an initial surge of serum testoste...
متن کاملLHRH Agonists for the Treatment of Prostate Cancer: 2012.
The most recent guidelines on prostate cancer screening from the American Urological Association (2009), the National Comprehensive Cancer Network (2011), and the European Association of Urology (2011), as well as treatment and advances in disease monitoring, have increased the androgen deprivation therapy (ADT) population and the duration of ADT usage as the first-line treatment for metastatic...
متن کاملAntiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
The therapeutic options for the treatment of androgen-independent prostatic cancers are rather limited; this is mainly because our understanding of the local mechanisms involved in the control of androgen-independent proliferation of the tumor is still very poor. The present experiments have been performed to verify whether luteinizing hormone-releasing hormone (LHRH) agonists may possess a dir...
متن کاملAutocrine-inhibitory LHRH Loop Prostate Cancer Cell Line DU 145: Evidence for an Hormone (LHRH) Agonists on Human Androgen-independent Antiproliferative Effects of Luteinizing Hormone-releasing
The therapeutic options for the treatment of androgea-independent prostatic cancers are rather limited; this Is mainly because our under standing of the local mechanisms involved In the control of androgen independent proliferation of the tumor is stlH very poor. The present experlmeats have been performed to verify whether luteinizing hormone releasing hormone (LHRH) agonists may possess a dir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Central European Journal of Urology
سال: 2015
ISSN: 2080-4873
DOI: 10.5173/ceju.2015.513